Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,707 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.
Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Yumita S, Nakagawa M, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Ozawa Y, Kawasaki Y, Kurokawa T, Hanaoka H, Tsuji H, Kato N. Ogasawara S, et al. Among authors: ogawa k. BMJ Open. 2022 Apr 8;12(4):e059779. doi: 10.1136/bmjopen-2021-059779. BMJ Open. 2022. PMID: 35396315 Free PMC article.
Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment.
Mukai S, Kanzaki H, Ogasawara S, Ishino T, Ogawa K, Nakagawa M, Fujiwara K, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Shiina M, Ota M, Ikeda JI, Takiguchi Y, Ohtsuka M, Kato N. Mukai S, et al. Among authors: ogawa k. JGH Open. 2021 Oct 1;5(11):1266-1274. doi: 10.1002/jgh3.12660. eCollection 2021 Nov. JGH Open. 2021. PMID: 34816012 Free PMC article.
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.
Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y, Kato N. Kobayashi K, et al. Among authors: ogawa k. Liver Cancer. 2021 Dec 6;11(1):48-60. doi: 10.1159/000519868. eCollection 2022 Jan. Liver Cancer. 2021. PMID: 35222507 Free PMC article.
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.
Arai J, Otoyama Y, Fujita KI, Goto K, Tojo M, Katagiri A, Nozawa H, Kubota Y, Takahashi T, Ishida H, Tsunoda T, Matsumoto N, Ogawa K, Nakagawa R, Muroyama R, Kato N, Yoshida H. Arai J, et al. Among authors: ogawa k. BMC Cancer. 2022 Apr 20;22(1):428. doi: 10.1186/s12885-022-09512-5. BMC Cancer. 2022. PMID: 35443621 Free PMC article.
Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis.
Ozeki Y, Kanogawa N, Ogasawara S, Ogawa K, Ishino T, Nakagawa M, Fujiwara K, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Nakamura M, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Muroyama R, Tawada A, Chiba T, Arai M, Kato J, Ikeda JI, Takiguchi Y, Kato N. Ozeki Y, et al. Among authors: ogawa k. Int J Clin Oncol. 2022 Sep;27(9):1459-1466. doi: 10.1007/s10147-022-02195-9. Epub 2022 Jun 15. Int J Clin Oncol. 2022. PMID: 35704154
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience.
Ogawa K, Kanzaki H, Chiba T, Ao J, Qiang N, Ma Y, Zhang J, Yumita S, Ishino T, Unozawa H, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Kanda T, Maruyama H, Mimura N, Kato J, Motohashi S, Kato N. Ogawa K, et al. J Cancer. 2022 May 16;13(8):2656-2661. doi: 10.7150/jca.71494. eCollection 2022. J Cancer. 2022. PMID: 35711837 Free PMC article.
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus.
Ma Y, Nakamoto S, Ao J, Qiang N, Kogure T, Ogawa K, Nakagawa M, Fujiwara K, Iwanaga T, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Chiba T, Kato J, Kato N. Ma Y, et al. Among authors: ogawa k. Int J Mol Sci. 2022 Oct 10;23(19):12015. doi: 10.3390/ijms231912015. Int J Mol Sci. 2022. PMID: 36233317 Free PMC article.
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma.
Qiang N, Ao J, Nakamura M, Chiba T, Kusakabe Y, Kaneko T, Kurosugi A, Kogure T, Ma Y, Zhang J, Ogawa K, Kan M, Iwanaga T, Sakuma T, Kanayama K, Kanzaki H, Kojima R, Nakagawa R, Kondo T, Nakamoto S, Muroyama R, Kato J, Mimura N, Ma A, Jin J, Kato N. Qiang N, et al. Among authors: ogawa k. Int Immunopharmacol. 2023 May;118:110068. doi: 10.1016/j.intimp.2023.110068. Epub 2023 Mar 29. Int Immunopharmacol. 2023. PMID: 37001386
5,707 results